

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No. **1625**  
12582

In Re Application Of: **Lloyd S. Gray, et al.**

Serial No.  
**09/544,968**

Filing Date  
**April 7, 2000**

Examiner  
**Unassigned**

Group Art Unit  
**Unassigned**

Title: **ANTICANCER CALCIUM CHANNEL BLOCKERS**

**RECEIVED**

**NOV 21 2000**

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**TECH CENTER 1000/2500**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
  2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
12582

In Re Application Of: Lloyd S. Gray, et al.


Serial No.  
09/544,968

Filing Date  
April 7, 2000

Examiner  
Unassigned

Group Art Unit  
Unassigned

Title: ANTICANCER CALCIUM CHANNEL BLOCKERS



RECEIVED

NOV 21 2000

TECH CENTER 1500/2000

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-3886/RCT as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_ (Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on 11/13/00 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

*Janet Giordano*  
Signature of Person Mailing Correspondence

Janet Giordano  
Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

*Mark J. Cohen*  
Signature

Mark J. Cohen  
Registration No. 32,211

Dated: November 13, 2000

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516)742-4343

CC:



PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** Lloyd S. Gray, et al.

**Examiner:** Unassigned

**Serial No:** 09/544,968

**Art Unit:** Unassigned

**Filed:** April 7, 2000

**Docket:** 12582

**For:** ANTICANCER CALCIUM CHANNEL  
BLOCKERS

**Dated:** November 13, 2000

Assistant Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20231

RECEIVED  
NOV 21 2000  
TECH CENTER (6047500)

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. §§1.56, 1.97 and 1.98, applicants are making of record art for consideration by the United States Patent and Trademark Office. Some of this art was encountered in the course of the prosecution of the corresponding PCT application, and is cited in the International Search Report, a copy of which is enclosed herewith.


The cited art is specifically listed on the accompanying PTO-1449 and hereinbelow:

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on November 13, 2000.

Dated: November 13, 2000

  
Janet Giordano

U.S. Patent No. 3,732,247, issued May 8, 1973, to Helsley, et al.

U.S. Patent No. 4,908,365, issued March 13, 1990, to Buzas, et al.

U.S. Patent No. 4,957,927, issued September 18, 1990 to Ferrand, et al.

International Application No. WO 97/10212.

International Application No. WO 92/05172.

European Patent No. EP 0 805 147 A1.

Benzaquen, Laura R., et al. "Clotrimazole inhibits cell proliferation in vitro and in vivo", Nature Medicine, Vol. 1, No. 6, June 1995, pp. 524-540.

Cohen, R.B., et al. "Pilot study of pharmacologic inhibition of calcium entry blockers in the treatment of advanced breast and prostate cancer", Proc. Annu. Meet. Am. Soc. Clin. Oncol., Vol. 16, 1997, p. 538a.

Densmore John J., et al. "A voltage-gated calcium channel is linked to the antigen receptor in Jurkat T lymphocytes", Febs Letters, Vol. 312, No. 2,3, Nov. 1992, p. 161-164.

Densmore, John J., et al. "A voltage-operable current is involved in  $Ca^{2+}$  entry in human lymphocytes whereas  $I_{CRAC}$  has no apparent role", Am. J. Physiol., Vol. 271, (1996).

Haverstick, Doris M., "Calmodulin regulation of  $Ca^{2+}$  entry in Jurkat T cells", Cell Calcium, 23(6):361-367, 1998.

Wikstrom, Peter, et al. "Additional peptidyl diazomethyl ketones, including biotinyl derivatives, which affinity-label calpain and related cysteinyl proteinases", J. Enzyme Inhibition, 1993, Vol. 6, pp. 259-269.

International Search Report (International Application No. PCT/US00/09310).

For the convenience of the United States Patent and Trademark Office, a copy of each of the publications listed hereinabove is enclosed herewith.

Consideration of this Information Disclosure Statement is respectfully requested since the art provided may be material to the examination of the present application, as defined in 37 C.F.R. §1.56.

RECEIVED  
NOV 21 2000  
TECH CENTER (600/2200)

Inasmuch as this Information Disclosure Statement is being submitted prior to the issuance of a first Official Action on the merits, no fee or certificate is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mark J. Cohen". The signature is fluid and cursive, with the first name "Mark" being more prominent.

Mark J. Cohen  
Registration No. 32,211

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530

MJC/bb